Security key
68232V884
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW)
CUSIP: 68232V884
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.01 per share
- Shares outstanding
- 16,062,541
- Total 13F shares
- 1,263,487
- Share change
- -468,822
- Total reported value
- $1,869,962
- Price per share
- $1.48
- Number of holders
- 19
- Value change
- -$1,075,287
- Number of buys
- 6
- Number of sells
- 8
Report period
Q2 2025
Institutions
19
Top holders
10
TRAW full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Traws Pharma, Inc. SEC filings
Traws Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68232V884
Recent filing periods:
Top shareholders of TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. |
13D/G
13F
|
Company |
9.9%
|
302,252
|
$462,446 | $0 | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.8%
|
605,531
|
$1,392,721 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
2.6%
|
421,781
|
$970,096 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.1%
|
330,000
|
$759,000 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.1%
|
175,000
|
$402,500 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
33,379
|
$76,775 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
33,305
|
$76,602 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.18%
|
28,493
|
$65,534 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.09%
|
14,323
|
$32,943 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.08%
|
13,173
|
$30,298 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.06%
|
10,071
|
$23,163 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.06%
|
9,956
|
$22,899 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
3,261
|
$7,500 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
725
|
$1,668 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
507
|
$1,166 | — | 31 Mar 2025 | |
| Vermillion & White Wealth Management Group, LLC |
13F
|
Company |
0%
|
96
|
$221 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
76
|
$175 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
2
|
$5 | — | 31 Mar 2025 | |
| Viriom, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,645,100
|
$1,480,590 | — | 03 Apr 2024 | |
| TPAV, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
192,696
mixed-class rows
|
— | — | 02 Apr 2025 | |
| Steven M. Fruchtman |
3/4/5
|
PRESIDENT, CHIEF EXECUTIVE OFF, Director |
—
mixed-class rows
|
121,014
mixed-class rows
|
$98,282 | — | 13 Mar 2024 | |
| Abraham N. Oler |
3/4/5
|
SVP Corp Dev & Gen Counsel |
—
mixed-class rows
|
96,197
mixed-class rows
|
$36,818 | — | 07 Feb 2022 | |
| Mark Patrick Guerin |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
44,755
mixed-class rows
|
$23,400 | — | 05 Feb 2025 | |
| Mark S. Gelder MD |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
82,667
mixed-class rows
|
$13,847 | — | 13 Mar 2023 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
—
class O/S missing
|
1
|
$1 | — | 31 Mar 2025 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
164,000
|
— | — | 16 Sep 2024 | |
| Victor M. Moyo |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
125,000
|
— | — | 02 Oct 2023 | |
| James J. Marino |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Jerome Groopman |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Peter Atadja |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Viren Mehta |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 |
Institutional Holders of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) as of Q2 2025
As of 30 Jun 2025,
Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,263,487 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, TWO SIGMA SECURITIES, LLC, TWO SIGMA INVESTMENTS, LP, VANGUARD GROUP INC, and BlackRock, Inc..
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
19
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.